Neurobiological Tech (NTII) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII)

NTII 0.0001000

0.0%

Nov 28 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John McCarthy who wrote (742)	1/5/2000 8:37:00 AM
From: Dr. John M. de Castro	Read Replies (1) of 1494

The results of the Phase II trial of memantine for Neuropathic pain should be out within the next two weeks. The data are almost ready for analysis and the blind should be broken early next week. This is major. If the results are positive and the early indications are that they are, then, NTII becomes a very valuable company. If they are not positive, I will be very disappointed, but, the company will still have viable AIDS Dementia Complex and senile dementia indications for memantine. Best regards John de C

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next